Research

Mixed

Faecal Microbiota Transplantation (FMT) from lean donors shows promise for improving insulin sensitivity in metabolic syndrome, but current human evidence is limited, small, and unreplicated.

FMT from lean donors may improve insulin sensitivity, but it is not yet a standard or proven treatment for diabetes due to limited and unreplicated human data. Do not pursue this outside of clinical trials.

LimitedQualifiesLOW confidence
the current evidence for FMT as a therapeutic tool to improve glycaemic control and/or insulin sensitivity is very limited
Louise Brunkwall et al. · Diabetologia · 2017

Why this rating

Based on a single small study (n=18) that did not report glucose levels and has not been replicated.

Source

The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities

Louise Brunkwall et al. · Diabetologia · 2017

DOI 10.1007/s00125-017-4278-3

narrative_reviewCited 355×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →